AMRX · Amneal Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $722.52M | - | $784.51M | $724.51M | $695.42M | - | $702.47M | $701.78M | $659.19M | - |
| Cost of Revenue | $402.41M | - | $510.54M | $438.25M | $439.53M | - | $432.91M | $451.83M | $421.13M | - |
| Gross Profit | $320.11M | - | $273.97M | $286.25M | $255.89M | - | $269.56M | $249.95M | $238.06M | - |
| R&D | $38.38M | - | $63.35M | $47.96M | $40.04M | - | $61.10M | $36.05M | $39.30M | - |
| SG&A | $138.86M | - | $137.81M | $124.27M | $118.29M | - | $118.69M | $116.46M | $112.59M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $141.77M | - | $70.34M | $111.37M | $100.35M | - | $88.81M | $95.47M | ($10.75M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $2.18M | - | ($23.36M) | $16.10M | $12.87M | - | $3.67M | $3.62M | $6.16M | - |
| Net Income | $62.26M | - | $2.37M | $22.42M | $12.20M | - | ($156.0K) | $5.99M | ($91.64M) | - |
| EPS - Basic | $0.20 | - | $0.01 | $0.07 | $0.04 | - | $0.00 | $0.02 | ($0.30) | - |
| EPS - Diluted | $0.19 | - | $0.01 | $0.07 | $0.04 | - | $0.00 | $0.02 | ($0.30) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197.66M | $282.03M | $201.25M | $71.54M | $59.19M | $110.55M | $74.01M | $43.77M | $46.52M | $91.54M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $641.62M | $606.30M | $614.50M | $608.97M | $601.43M | $612.45M | $596.36M | $575.62M | $570.65M | $581.38M |
| Accounts Payable | - | - | $266.36M | $205.81M | $258.69M | - | $235.00M | $199.58M | $175.32M | - |
| Current Assets | $1.80B | $1.91B | $1.84B | $1.58B | $1.51B | $1.59B | $1.51B | $1.49B | $1.38B | $1.38B |
| Total Assets | $3.54B | $3.68B | $3.60B | $3.42B | $3.37B | $3.50B | $3.46B | $3.51B | $3.46B | $3.47B |
| Current Liabilities | $728.05M | $881.63M | $862.11M | $1.11B | $1.08B | $1.13B | $1.10B | $1.11B | $834.39M | $846.60M |
| Long-term Debt | $2.57B | $2.57B | $2.57B | $2.15B | $2.15B | $2.16B | $2.17B | $2.18B | $2.38B | $2.39B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($45.41M) | ($70.79M) | ($109.46M) | ($112.12M) | ($131.67M) | ($109.27M) | ($93.43M) | ($57.47M) | ($63.72M) | $19.78M |
| Retained Earnings | ($472.75M) | ($535.00M) | ($570.08M) | ($572.45M) | ($594.87M) | ($607.06M) | ($575.98M) | ($575.83M) | ($581.82M) | ($490.18M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($26.74M) | - | - | - | $7.41M | - | - | - | ($4.41M) | - |
| Investing Cash Flow | ($21.71M) | - | - | - | ($17.80M) | - | - | - | ($19.76M) | - |
| Financing Cash Flow | ($59.05M) | - | - | - | ($39.17M) | - | - | - | ($23.16M) | - |
| CapEx | $8.18M | - | - | - | $13.16M | - | - | - | $9.20M | - |
| Free Cash Flow | ($34.92M) | - | - | - | ($5.75M) | - | - | - | ($13.61M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 44.3% | - | 34.9% | 39.5% | 36.8% | - | 38.4% | 35.6% | 36.1% | - |
| Operating margin | 19.6% | - | 9.0% | 15.4% | 14.4% | - | 12.6% | 13.6% | -1.6% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | 8.6% | - | 0.3% | 3.1% | 1.8% | - | -0.0% | 0.9% | -13.9% | - |
| Free cash flow margin | -4.8% | - | - | - | -0.8% | - | - | - | -2.1% | - |
| FCF / Net income | -0.56 | - | - | - | -0.47 | - | - | - | 0.15 | - |
| R&D / Revenue | 5.3% | - | 8.1% | 6.6% | 5.8% | - | 8.7% | 5.1% | 6.0% | - |
| SG&A / Revenue | 19.2% | - | 17.6% | 17.2% | 17.0% | - | 16.9% | 16.6% | 17.1% | - |
| Effective tax rate | 3.4% | - | - | 41.8% | 51.3% | - | 104.4% | 37.6% | - | - |
| Return on assets | 1.8% | - | 0.1% | 0.7% | 0.4% | - | -0.0% | 0.2% | -2.7% | - |
| Return on equity | -137.1% | - | -2.2% | -20.0% | -9.3% | - | 0.2% | -10.4% | 143.8% | - |
| Return on invested capital | 5.4% | - | 2.3% | 3.2% | 2.5% | - | 2.1% | 2.8% | -0.4% | - |
| Liquidity | ||||||||||
| Current ratio | 2.47 | 2.17 | 2.13 | 1.43 | 1.40 | 1.41 | 1.38 | 1.33 | 1.65 | 1.63 |
| Quick ratio | 1.59 | 1.48 | 1.42 | 0.88 | 0.84 | 0.86 | 0.84 | 0.82 | 0.97 | 0.94 |
| Cash ratio | 0.27 | 0.32 | 0.23 | 0.06 | 0.06 | 0.10 | 0.07 | 0.04 | 0.06 | 0.11 |
| Leverage | ||||||||||
| Debt / Equity | -56.50 | -36.23 | -23.45 | -19.14 | -16.36 | -19.78 | -23.22 | -37.89 | -37.31 | 120.62 |
| Debt / Assets | 0.72 | 0.70 | 0.71 | 0.63 | 0.64 | 0.62 | 0.63 | 0.62 | 0.69 | 0.69 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -77.96 | -51.96 | -32.89 | -30.53 | -25.56 | -32.04 | -37.04 | -61.08 | -54.24 | 175.55 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.22 | 0.21 | 0.21 | - | 0.20 | 0.20 | 0.19 | - |
| Inventory turnover | 0.63 | - | 0.83 | 0.72 | 0.73 | - | 0.73 | 0.78 | 0.74 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 582d | - | 439d | 507d | 499d | - | 503d | 465d | 495d | - |
| Days payable outstanding | - | - | 190d | 171d | 215d | - | 198d | 161d | 152d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 65.4x | - | 1001.0x | 115.6x | 209.5x | - | - | 317.5x | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 5.7x | - | 4.1x | 3.6x | 3.9x | - | 3.7x | 2.9x | 2.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 3.9% | - | 11.7% | 3.2% | 5.5% | - | 13.3% | 17.1% | 18.2% | - |
| Revenue CAGR (3y) | 9.0% | - | 12.9% | 9.0% | 11.8% | - | 9.9% | 9.5% | 10.2% | - |
| Revenue CAGR (5y) | 7.9% | - | 8.6% | 9.3% | 6.9% | - | 13.2% | 11.6% | 8.1% | - |
| Gross profit growth (YoY) | 25.1% | - | 1.6% | 14.5% | 7.5% | - | 15.9% | 13.6% | 33.6% | - |
| Operating income growth (YoY) | 41.3% | - | -20.8% | 16.7% | - | - | 17.4% | 19.2% | - | - |
| Net income growth (YoY) | 410.5% | - | - | 274.0% | - | - | - | -73.0% | -486.3% | - |
| EPS growth (YoY) | 375.0% | - | - | 250.0% | - | - | - | -75.0% | -500.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | -41.5% | - | - |
| EPS CAGR (5y) | 36.6% | - | - | - | -44.8% | - | - | - | - | - |
| FCF growth (YoY) | -506.8% | - | - | - | 57.7% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 65.5% | 35.2% | -17.2% | -95.1% | -106.6% | - | - | - | - | -93.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$3.02B totalAffordable Medicines Segment$1.75B · 57.8%
Av KARESegment$744.73M · 24.7%
Specialty Segment$528.51M · 17.5%
Product / service
$5.28B totalSubtotal Dosage Forms$1.73B · 32.8%
Oral Solid$726.38M · 13.8%
Subtotal Therapeutic Classes$528.01M · 10.0%
Distribution Service$408.46M · 7.7%
Central Nervous System$333.42M · 6.3%
Government Label$270.11M · 5.1%
Other Dosage Forms$252.42M · 4.8%
Ephinephrine Auto Injector$232.80M · 4.4%
Transdermal$187.51M · 3.6%
Injectable$161.24M · 3.1%
Hormonal Allergy$154.93M · 2.9%
Biosimilar$100.23M · 1.9%
Oral Liquid$72.82M · 1.4%
Other Therapeutic Classes$39.66M · 0.8%
Institutional$35.38M · 0.7%
Product And Service Other$30.79M · 0.6%
International$12.13M · 0.2%
License Agreement$500.0K · 0.0%
Geographic
$1.75B totalUS$1.75B · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Amneal Pharmaceuticals against the 5 most active filers in the same SIC group.